Jeff Engelman (L) and Josh Bilenker
Loxo founder Josh Bilenker, Novartis oncology leader Jeff Engelman join forces to debut cancer R&D player
Josh Bilenker has been busy since leaving Eli Lilly at the end of January.
Earlier on Monday he put out word on LinkedIn that …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
